Rigaku Raman Upgrades Handheld Analyzer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rigaku Raman Upgrades Handheld Analyzer


Rigaku Raman Technologies announced an updated version of the FirstGuard handheld Raman analyzer at Pittcon 2013. The analyzer operates at 1064 nm wavelength, enabling it to identify a broader range of raw materials and provide very rapid validation in comparison to 785 nm wavelength excitation products. Features include an integrated bar code reader enabling for GMP Raw Material Identification applications, user account management, upgraded data reporting and archiving, and improved data and operator security to support integration into FDA regulated manufacturing environments, the company reports. The analyzer is equipped with an integrated vial holder and hot swappable lithium ion battery, and is configured with secure software for 21 CRF part 11 compliance.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here